Crohn's Disease (CD)

Immunology·MeSH: Crohn Disease

Prevalence

201.0 / 100K

Incidence

6.0 / 100K/yr

8 drugs in development·7 companies·3 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
wezlana	AMGEN INC (AMGN)

Phase 3(2)

Drug	Company
ozanimod	CELGENE CORP /DE/ (CELG)
ustekinumab	AbbVie Inc. (ABBV)

Phase 2(2)

Drug	Company
fxr314	VivoSim Labs, INC. (VIVS)
PDA-001	Celularity Inc. (CELU)

Phase 4(3)

Drug	Company
Risankizumab	AbbVie Inc. (ABBV)
vedolizumab iv	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
vedolizumab iv	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

BioSniper tracks 8 drugs in development for Crohn's Disease (CD) across 7 companies.

There are 3 clinical trials targeting Crohn's Disease (CD) tracked by BioSniper.

The estimated prevalence of Crohn's Disease (CD) is approximately 201.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.